Roy Baynes Sells 4,500 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Key Points

• Director Roy Baynes sold 4,500 shares at an average price of $46.65 on May 5 for about $209,925, leaving him with 37,500 shares (a 10.71% reduction); the sale was executed under a pre‑arranged Rule 10b5‑1 plan and disclosed to the SEC.
• Travere beat Q1 EPS estimates with $0.05 versus a -$0.24 consensus and reported $127.2 million in revenue (up 55.6% year‑over‑year), though the company still shows a negative net margin and return on equity.
• Analysts have trended bullish, with notable upgrades including TD Cowen raising its target to $60 and Wells Fargo to $50, leaving a consensus rating of "Moderate Buy" and an average target around $47.83.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) Director Roy Baynes sold 4,500 shares of the firm's stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $46.65, for a total transaction of $209,925.00. Following the completion of the transaction, the director directly owned 37,500 shares in the company, valued at approximately $1,749,375. This represents a 10.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Price Performance

Shares of Travere Therapeutics stock traded down $0.10 on Wednesday, reaching $44.70. 2,390,035 shares of the stock were exchanged, compared to its average volume of 2,890,153. The company has a debt-to-equity ratio of 3.16, a quick ratio of 2.70 and a current ratio of 3.13. The firm has a market cap of $4.16 billion, a PE ratio of -194.33 and a beta of 1.13. The firm's 50 day moving average is $32.59 and its 200-day moving average is $32.83. Travere Therapeutics, Inc. has a one year low of $13.88 and a one year high of $48.61.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The business had revenue of $127.20 million for the quarter, compared to analysts' expectations of $136.23 million. During the same period last year, the firm posted ($0.47) earnings per share. The firm's quarterly revenue was up 55.6% compared to the same quarter last year. As a group, analysts anticipate that Travere Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on TVTX shares. TD Cowen boosted their price target on Travere Therapeutics from $45.00 to $60.00 and gave the stock a "buy" rating in a report on Tuesday. Wedbush lifted their target price on Travere Therapeutics from $53.00 to $55.00 and gave the company an "outperform" rating in a research report on Tuesday. Wall Street Zen downgraded Travere Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 21st. Wells Fargo & Company lifted their price target on shares of Travere Therapeutics from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Wednesday. Finally, Piper Sandler upgraded shares of Travere Therapeutics from a "neutral" rating to an "overweight" rating and set a $49.00 price objective for the company in a research report on Tuesday, April 14th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Travere Therapeutics has an average rating of "Moderate Buy" and an average target price of $47.83.

Hedge Funds Weigh In On Travere Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Arizona State Retirement System raised its position in Travere Therapeutics by 1.5% in the third quarter. Arizona State Retirement System now owns 24,964 shares of the company's stock valued at $597,000 after purchasing an additional 375 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Travere Therapeutics by 69.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company's stock worth $45,000 after purchasing an additional 487 shares during the last quarter. Comerica Bank increased its stake in shares of Travere Therapeutics by 77.5% in the fourth quarter. Comerica Bank now owns 1,127 shares of the company's stock valued at $43,000 after buying an additional 492 shares during the period. ProShare Advisors LLC increased its stake in shares of Travere Therapeutics by 4.1% in the fourth quarter. ProShare Advisors LLC now owns 19,007 shares of the company's stock valued at $726,000 after buying an additional 756 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Travere Therapeutics by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,348 shares of the company's stock valued at $166,000 after buying an additional 902 shares during the last quarter.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a "buy" rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an "overweight" rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a "Buy" and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.